Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Offer SARS GeneChip

 NEW YORK, May 6 - Affymetrix today said it has designed a GeneChip-brand microarray for resequencing different isolates of the coronavirus that causes severe acute respiratory syndrome, or SARS.

 

The chip was designed using the sequence published by the Canadian team at the BC CancerCenter, the US Centers for Disease control sequence, and sequences by Asian scientists, the company said. Scientists in Singapore, Hong Kong, and Beijing have published sequences of the virus, following the Canadian and US teams.

 

The new array includes the entire 29,700 base pairs in the virus and is designed for rapid resequencing to study possible mutations in different isolates, according to the company. This resequencing could allow scientists to categorize these isolates into subtypes, and also, in comparing the sequence to specific clinical data, understand why some strains are more dangerous than others. Epidemiologists can also use the array to track the virus' evolution over time in different populations and different areas, the company said.

 

This array is part of Affymetrix CustomSeq line of arrays for pathogens and other applications.

 

"We hope that by getting this powerful CustomSeq array into the hands of scientists, we can contribute to understanding SARS and the search for treatments," Greg Yap,  Senior Marketing Director, DNA Analysis, at Affymetrix, said in a statement.

 

Combimatrix has also made available a SARS microarray, and other companies have offered PCR diagnostic kits for SARS.

 

GenomeWeb/Newsletters' coverage of SARS  

 

DeRisi Lab Uses its Viral Microarray To Help CDC Zero in on SARS Mystery  (BioArray News, April 4, 2003)

Canadian Team Sequencing SARS Virus   (Apr 9, 2003)
CDC Hails SARS Virus Sequencing, Discusses PCR Diagnostic Development    (Apr 14, 2003)

CDC Completes SARS Virus Genome Draft On Heels of Canadian Team   (April 14, 2003)

Canadian Team Leader: SARS Coronavirus Genome Has 11 Novel ORFs   (April 15, 2003)
CombiMatrix Creates Microarray Based on SARS Genome Data   (April 16, 2003)
Coronavirus Linked to SARS: WHO (April 16, 2003) 

Singapore Genome Institute Joins SARS Sequencing Fray  (April 16, 2003)

Singapore Team Finishes SARS Virus Genome; Canadian Scientists Identify Viral Proteins  (April 17, 2003)

Beijing Group Publishes Four SARS Sequences from Mainland China, Claims To Have One-Hour SARS Test   (April 21, 2003)

University of Manitoba Proteomics Researchers Tackle SARS Virus Proteins (ProteoMonitor, April 21, 2003)
CombiMatrix to Provide its SARS Arrays Free to Select Governments, Academia (April 23, 2003)

CombiMatrix's Ali Arjomand on Developing a SARS Microarray (BioArray News, April 25, 2003)

NCID said to Launch PCR Test for SARS Next Week (SNPTech Reporter, April 25, 2003)

RNAi Roundup: Qiagen Offers RNAi Expertise to SARS Scientists; Antisense Beats RNAi to SARS Drug Starting Line...(April 25, 2003)

Roche to Launch RT-PCR-based SARS Diagnostic by July (April 28, 2003)

Canadian, US, Chinese Teams Publish SARS Genome Sequence (May 2, 2003)

Focus Tech Claims First RT-PCR SARS Diagnostic (May 5, 2003)


 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.